Siftr Bio

Siftr Bio is a biotechnology company developing novel linker chemistry for antibody-drug conjugates.

Current ADC linkers have limited diversity and insufficient selectivity, contributing to off-target toxicity that restricts their therapeutic application.

Siftr's platform screens enzyme-responsive linker candidates against human patient tumour tissue, integrating high-throughput chemistry with ultrasensitive proteomics to identify linkers with improved precision and a broader therapeutic window across oncology indications.